Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651151 | 1.00 | STS (0.47) | STSCCR5GPR119JAK2JAK1 | |
| SCHEMBL30071078 | 1.00 | STS (0.47) | STSCCR5GPR119JAK2JAK1 | |
| SCHEMBL17483520 | 0.91 | STS (0.47) | STSCCR5GPR119JAK2JAK1 | |
| SCHEMBL798874 | 0.85 | STS (0.47) | STSGPR119KMT2AL3MBTL1NR1H2 | |
| SCHEMBL10257295 | 0.85 | STS (0.47) | STSGPR119KMT2AL3MBTL1NR1H2 | |
| SCHEMBL788451 | 0.85 | STS (0.47) | STSGPR119KMT2AL3MBTL1NR1H2 | |
| SCHEMBL6785103 | 0.84 | NR1H2 (0.47) | STSGPR119JAK2JAK1KMT2A | |
| SCHEMBL2226628 | 0.83 | MAPT (0.45) | STSGPR119JAK2JAK1KMT2A | |
| SCHEMBL2226624 | 0.83 | MAPT (0.45) | STSGPR119JAK2JAK1KMT2A | |
| SCHEMBL993829 | 0.82 | CCR5 (0.58) | CCR5GPR119JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | STS 4555/4885CCR5 440/4885GPR119 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.